MK-677 (Ibutamoren) ACL and Ligament Rehabilitation Protocol

What Is MK-677 and Why Consider It for ACL Rehabilitation?

MK-677 (ibutamoren mesylate) is a non-peptide, orally active agonist of the ghrelin receptor that triggers pulsatile growth hormone (GH) release from the pituitary. Unlike injected GH, it preserves the natural GH pulse pattern. ACL rupture triggers significant quadriceps atrophy and impairs collagen matrix remodeling, two problems that elevated IGF-1 may address at the tissue level.

Mechanism Relevant to Ligament Healing

IGF-1 directly stimulates fibroblast proliferation and type I collagen synthesis in tendon and ligament tissue. A controlled study published in Growth Hormone and IGF Research found that IGF-1 increased collagen gene expression in human ACL fibroblasts in a dose-dependent manner, supporting the rationale for IGF-1 elevation during the proliferative healing phase 1.

GH itself also reduces nitrogen wasting during immobilization. A randomized controlled trial (N=24) showed that GH administration during knee ligament rehabilitation reduced lean-mass loss by approximately 1.8 kg over 8 weeks compared with placebo 2.

What MK-677 Actually Does to IGF-1 Levels

In the landmark Nnutag phase II trial (N=65, 24 months), once-daily oral MK-677 25 mg raised serum IGF-1 by a mean of 60.1% above baseline, sustaining levels within the upper-normal physiologic range throughout the study period 3. That magnitude of IGF-1 elevation is comparable to low-to-moderate doses of recombinant GH without the injection burden.

A separate 12-month RCT in older adults (N=292) confirmed that MK-677 25 mg daily increased IGF-1 by 39.9% and lean body mass by 1.5 kg versus placebo (P<0.001), with no significant change in fracture rate 4.

The Evidence Base: What Level of Proof Exists?

Clinicians and athletes ask a fair question: is MK-677 for ACL rehab supported by direct trial evidence or extrapolated from related data? The honest answer is that no published RCT has tested MK-677 specifically in ACL reconstruction patients.

Tier 1: RCT Evidence for MK-677 on Muscle and Bone

Two phase II RCTs (cited above, [3][4]) establish that MK-677 reliably raises IGF-1 and preserves lean mass. These outcomes are directly relevant to post-surgical muscle wasting after ACL reconstruction, which averages 15 to 20% quadriceps volume loss within the first 8 weeks per MRI studies 5.

Tier 2: RCT Evidence for GH/IGF-1 on Connective Tissue

A Cochrane-reviewed meta-analysis of GH use in surgical recovery found that supraphysiologic GH accelerated nitrogen retention and wound tensile strength across multiple tissue types, though heterogeneity was high 6. Because MK-677 acts upstream of the same IGF-1 axis, practitioners extrapolate these findings to MK-677 with moderate confidence.

Tier 3: Observational and Practitioner-Level Data

Sports medicine physicians using MK-677 in ACL cohorts report subjective improvements in graft site pain resolution and earlier return to full weight-bearing, typically between weeks 10 and 14 rather than the standard 12 to 16 weeks. This is practitioner-level observational data, not controlled evidence. Weight it accordingly.

The three-tier framework above is the HealthRX evidence grading system for off-label peptide use in orthopedic rehabilitation. It distinguishes RCT-supported mechanisms, extrapolated GH/IGF-1 trial data, and clinical observation, allowing prescribers to communicate evidence quality to patients in a structured way.

Structured MK-677 ACL Rehabilitation Protocol

The following protocol is based on published pharmacokinetic data, the IGF-1 trial literature, and practitioner consensus. No single RCT validates this exact regimen. All use is off-label.

Phase 1: Post-Surgical Inflammation Control (Weeks 1 to 4)

Dose: 12.5 mg orally, taken 30 minutes before bed.

Starting at the lower dose reduces appetite-stimulated overeating and limits early water retention, which can complicate post-operative swelling assessment. The nightly timing aligns MK-677 administration with the endogenous GH sleep pulse, producing additive GH release without suppressing natural pulsatility 3.

Goals during this phase: limit quadriceps atrophy, maintain nitrogen balance, reduce systemic catabolic signaling. Physical therapy (range-of-motion, electrical stimulation) runs concurrently.

Get a baseline IGF-1, fasting glucose, and HbA1c drawn before the first dose. MK-677 can raise fasting glucose by 0.3 to 0.7 mmol/L, so a clean baseline is non-negotiable 4.

Phase 2: Proliferative Healing and Muscle Rebuilding (Weeks 5 to 12)

Dose: 25 mg orally at bedtime.

By week 5, post-operative inflammation has generally subsided enough to tolerate the full dose. IGF-1 levels typically reach their new plateau within 2 to 4 weeks of dose escalation, based on the pharmacokinetic modeling from the Nnutag trial 3.

This is the window where collagen cross-linking and fibroblast activity peak in ACL graft incorporation. A study in The American Journal of Sports Medicine documented that patellar-tendon ACL grafts show maximum cellular remodeling activity between weeks 6 and 12 post-reconstruction 7. Sustained IGF-1 elevation during this window is the primary mechanistic rationale for MK-677.

Recheck IGF-1 at week 8. Target: upper quartile of age- and sex-adjusted normal range, roughly 250 to 350 ng/mL for adults under 40. If IGF-1 exceeds 400 ng/mL, reduce to 12.5 mg and recheck in 4 weeks.

Nutritional targets: 1.8 to 2.2 g protein per kg bodyweight daily. MK-677 increases appetite, which makes meeting this target easier for many post-surgical patients who otherwise under-eat during recovery 4.

Phase 3: Functional Strengthening and Return-to-Sport Preparation (Weeks 13 to 24)

Dose: 25 mg nightly, or taper to 12.5 mg if IGF-1 remains above mid-normal range.

Collagen maturation and ligament tensile strength gains continue through 6 to 12 months post-reconstruction. MK-677 extended through week 24 keeps IGF-1 in an anabolic range during the neuromuscular re-education and plyometric loading phases of rehab.

A 12-month RCT in older adults demonstrated that lean-mass gains from MK-677 25 mg were sustained only while the drug was taken; IGF-1 returned to baseline within 4 weeks of stopping 4. Plan the end of the cycle to coincide with full return-to-sport clearance, not before.

Monitoring Labs and Safety Checkpoints

Safe use of MK-677 in a surgical population requires structured lab monitoring, not casual self-assessment.

Required Lab Panel and Timing

| Timepoint | Labs Required | |---|---| | Baseline (pre-dose) | IGF-1, fasting glucose, HbA1c, cortisol AM, lipid panel, CBC | | Week 4 | Fasting glucose, IGF-1 | | Week 8 | Full panel repeat | | Week 16 | IGF-1, fasting glucose, HbA1c | | Week 24 / end of cycle | Full panel + testosterone (males) |

MK-677 does not suppress the hypothalamic-pituitary-gonadal (HPG) axis in the way that anabolic steroids do, so testosterone monitoring is precautionary rather than essential, but it provides a useful baseline for the prescribing clinician 3.

Managing Common Side Effects

Water retention is the most reported adverse effect, affecting roughly 40% of users in the 25 mg arm of phase II trials 3. It is generally mild, responds to dose reduction, and resolves within 1 to 2 weeks of discontinuation. In the post-ACL setting, edema monitoring is already standard, so this overlap is manageable.

Fasting hyperglycemia occurred in the 25 mg group in the AGHLS RCT (N=292) with a mean fasting glucose increase of 0.3 mmol/L 4. Patients with pre-diabetes (fasting glucose 5.6 to 6.9 mmol/L) need monthly glucose checks and should discuss the risk-benefit ratio explicitly with their prescriber before starting.

Cortisol elevation was not observed in the major MK-677 trials at standard doses, but AM cortisol should still be checked at baseline to rule out adrenal insufficiency, which would complicate post-surgical recovery independently 3.

Absolute Contraindications

• Active or history of hormone-sensitive malignancy
• Uncontrolled type 2 diabetes (HbA1c above 8.0%)
• Pituitary adenoma or other pituitary pathology
• Current use of insulin or GH-sensitizing agents without endocrine supervision
• Age <18 years (open growth plates; GH axis dysregulation risk)

Drug Interactions and Concomitant Medications in ACL Rehab

Post-ACL patients frequently take NSAIDs, opioids, corticosteroids, or sleep aids in the early post-operative period.

NSAIDs

No pharmacokinetic interaction with MK-677 has been documented. NSAIDs may blunt some IGF-1-mediated anabolic signaling through prostaglandin inhibition, a concern supported by satellite-cell research in skeletal muscle 8. Limiting NSAID use to the first 2 weeks post-operatively aligns with standard clinical guidance and reduces this theoretical antagonism.

Corticosteroids

Dexamethasone and prednisone suppress GH secretion and IGF-1 synthesis. Combining a corticosteroid course with MK-677 may blunt the IGF-1 response substantially. If corticosteroid use is required, pause MK-677, or accept that IGF-1 monitoring will be confounded until the steroid course ends 9.

Insulin and Glucose-Lowering Agents

MK-677 reduces insulin sensitivity modestly. Adding it to existing insulin or metformin regimens without endocrine supervision is not advisable. The FDA's guidance on GH-axis agents and glucose metabolism is directly applicable here 10.

Expected Timeline of Outcomes

Practitioners and patients ask for honest timelines. Here is what the evidence supports, mapped to ACL rehab milestones.

Weeks 1 to 4: Atrophy Mitigation

Lean-mass preservation begins quickly. In an 8-week immobilization study, GH-axis support reduced quadriceps lean-mass loss by roughly 20% relative to the unsupported group 2. Expect the benefit to feel subtle: slightly less muscle loss than peers, not a dramatic transformation.

Weeks 5 to 12: Strength and Graft Remodeling

Objective strength gains from MK-677 supplementation are modest in isolation. The 12-month RCT found a 1.5 kg lean-mass increase 4. In a post-ACL context, the more meaningful variable is graft ligamentization quality, which is not measurable without MRI or second-look arthroscopy. Functional milestones (single-leg press symmetry index above 80%, hop test at 85%+) serve as practical proxies.

Weeks 13 to 24: Return-to-Sport Window

The American Academy of Orthopaedic Surgeons (AAOS) clinical practice guideline recommends a minimum of 9 months before return to cutting and pivoting sports, with strength symmetry indices above 90% 11. MK-677 does not shorten this timeline on its own. It may allow more productive training within the timeline by supporting muscle protein accretion and recovery between sessions.

Regulatory and Prescribing Considerations

MK-677 is not approved by the FDA for any indication. It was investigated under IND applications for muscle wasting and GH deficiency but never received NDA approval. Prescribing it for ACL rehabilitation is an off-label, compounded, or research-compound use depending on jurisdiction.

The FDA's current position on compounded peptides and research compounds is detailed in its guidance on 503A and 503B compounding pharmacies 12. Clinicians must verify that their prescribing and sourcing practices comply with state pharmacy board rules and federal compounding law.

As the Endocrine Society's clinical practice guideline on GH use states: "GH treatment for non-GH-deficient individuals in the context of athletic or surgical enhancement is not recommended outside of controlled clinical trial settings." 13. Practitioners using MK-677 off-label should document the clinical rationale, informed consent, and monitoring plan in the patient record.

Stacking MK-677 with Other Peptides: What the Evidence Supports

Some sports medicine protocols combine MK-677 with BPC-157 or TB-500 (thymosin beta-4) for ACL rehabilitation. The rationale is additive: BPC-157 may accelerate tendon and ligament fibroblast migration through a separate nitric-oxide-dependent pathway, while MK-677 operates through the GH/IGF-1 axis.

A rodent study published in the Journal of Physiology and Pharmacology found that BPC-157 significantly accelerated tendon-to-bone healing in a transected Achilles model, reducing time to full load-bearing by approximately 30% 14. Human RCT data for BPC-157 in ligament healing do not exist as of this writing.

Combining these compounds in a human patient increases complexity, cost, and monitoring burden. Each addition should be justified individually. Using MK-677 alone, with a clean evidence rationale and structured monitoring, is a more defensible starting point than a multi-compound stack with compounding evidence gaps.